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Abstract
Background Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease characterized by a signifi-
cant impairment of patients’ quality of life (QoL). It has been recently found that clinical severity of HS does not correlate
well with QoL. Therefore, it is important to enhance the evaluation of severity considering the disease burden on QoL.
Recently, a new graphical tool able to better describe HS burden, the so-called HIDRAdisk, has been introduced.
Objective To investigate the utility of HIDRAdisk in clinical practice before and after treatment and to analyse whether
specific factors such as age and gender may influence the outcomes in patients with moderate-to-severe HS.
Methods A single-centre retrospective study on 24 patients (13F/11M, mean age 38  15 years) with moderate-to-
severe HS was performed. Clinical data (disease severity and quality of life) were collected at baseline and after
12 weeks of adalimumab.
Results HIDRAdisk showed significantly better improvements in males (69.8  6.2–49.6  10.8) compared to females
(80.7  6.0–72.3  6.7), P <0.001. A significant correlation was found in the total population between HS severity val-
ues measured through the modified Sartorius score (mSS) and QoL measured through HIDRAdisk. As regards the rela-
tionship between disease outcomes and age, a trend for better HIDRAdisk outcomes in younger patients (<40 years)
compared to older ones was observed.
Conclusions HIDRAdisk appears as a complete and informative tool which can easily measure the global burden of
HS, guiding treatment choice and evaluating its efficacy.






Hidradenitis suppurativa (HS) is a chronic relapsing inflamma-
tory skin disease with nodules, abscesses and sinus tracts being
the main clinical manifestations.1 In addition, several comor-
bidities have been described in patients affected by HS, which
led to a significantly impairment on patients’ quality of life
(QoL).2 It has been recently found that clinical severity of HS
does not correlate well with QoL.3 Indeed, even when the disease
is clinically not very severe but the lesions are painful or located
on visible part of the body, HS may have a strong impact on
patients’ QoL. Therefore, it is necessary to evaluate the severity
of patients’ condition considering the disease burden on QoL.
Disease tools commonly used to describe patient discomfort
such as Dermatology Life Quality Index (DLQI), Skindex-16, as
well as Work Productivity and Activity Impairment (WPAI) are
not specific for HS and not useful on large numbers of patients.
Recently, a new graphical tool able to better describe HS burden,
the so-called HIDRAdisk, has been introduced.4,5 HIDRAdisk is
designed to be filled out by the patient with the dermatologist,
fostering their communication. Being a visual instrument, with
the answers shown graphically through a polygon, HIDRAdisk
gives an immediate and global picture of the disease burden, also
allowing patients and physicians to visualize the course of the
disease over time. When the burden of HS decreases, the area of
the polygon shrinks, providing an intuitive representation of the
progress achieved. Chiricozzi et al.4 firstly introduced this tool
through a mixed methodology: patient-only (patients affected
by HS for ≥24 months) and physician-only (with well-†HS Quality of Life Study Group members are listed in Appendix.
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documented experience in the research field) focus groups cre-
ated to capture the experience and perspective of the disease on
both sides; a modified Delphi method was then applied to assess
the level of convergence of both opinions about the items
selected and their weight within the disease experience of HS. A
rewording of the items was performed to further simplify the
questionnaire. A multicenter, longitudinal, observational study
on 140 patients was therefore conducted to validate the HIDRA-
disk compared with other validated questionnaires and to evalu-
ate its correlation with disease severity in patients with different
degree of HS severity.5 HIDRAdisk showed to have a strong cor-
relation with Skindex-16 and DLQI, and a good one with WPAI.
It also significantly correlated with disease severity.
We herein performed a retrospective study to investigate the
utility of HIDRAdisk in clinical practice before and after treat-
ment and to analyse whether specific factors such as age and
gender may influence the outcomes.
Material and methods
A single-centre retrospective study was performed among
patients with moderate-to-severe HS attending the outpatient
clinic of the Department of Clinical Medicine and Surgery, Sec-
tion of Dermatology of the University of Naples Federico II from
October 2017 to June 2018. Eligibility criteria were (i) moderate-
to-severe HS in patients aged ≥18 years; (ii) HS duration of at
least 6 months; and (iii) subjects starting adalimumab treatment
(160 mg on day 1, 80 mg on day 15 and 40 mg every week from
week 4). Patients affected by other skin diseases were excluded.
Written informed consent from all patients was provided. All
subjects received a complete dermatologic examination: disease
severity and quality of life were registered using the modified
Sartorius score (mSS) and HIDRAdisk, respectively. Data were
collected at baseline (T0) and after 12 weeks of adalimumab
(T12). Student’s t-test was used to calculate statistical differences
between baseline and week 12 (T12). P-values <0.05 were con-
sidered to be statistically significant. Spearman test was used to
evaluate the correlation among the parameters under study.
Results
A total of 24 patients (13 females, 11 males, mean age
38  15 years) were included. HS mean duration was of
6.7  3.4 years. As expected, the anatomical sites most commonly
involved were axillary regions (67%), groins (63%), gluteal regions
(43%) and inter-mammary region (21%). Involvement of gluteal
area prevailed in males (66%) whereas inter-mammary area in
females (54%). To note, four out of 24 patients (16.7%) received
for the first 4 weeks topical antibiotics or topical antiseptics con-
comitantly to adalimumab therapy. At baseline, mean mSS was
76.0  6.3, decreasing to 37.4  6.5 at T12, P < 0.001. A similar
trend was observed for HIDRAdisk with 75.7  8.22 decreasing to
61.95  14.4 at T12, P < 0.001, with pain, odour and daily activi-
ties showing the highest rate of reductions. Despite almost
comparable improvements in mSS between males and females
(from 73.7  6.4 to 37.3  5.3 in males and from 78  5.7 to
37.5  7.6 in females), HIDRAdisk showed significant better
improvements in males (69.8  6.2–49.6  10.8) compared to
females (80.7  6.0–72.3  6.7), P <0.001. However, a significant
correlation was found in the total population between severity HS
values measured through the mSS and the quality of life measured
through HIDRAdisk (Spearman r = 0.796). As regards the rela-
tionship between disease outcomes and age, we observed a trend
(although not statistically significant) for better HIDRAdisk out-
comes in younger (<40 years) compared to older adults
(≥40 years) despite no significant differences for mSS.
Discussion
Due to its chronic nature and frequently occurring relapses, HS
has a great impact on patients’ QoL.5 Hence, clinical disease
severity assessment is essential for the development of evidence-
based treatments. Several scoring systems are currently available
for the assessment of HS disease severity including Hurley stag-
ing, HS Physician’s Global Assessment (PGA), mSS and HS
Severity Index.6–9 Application of each of these assessments in
daily practice has both advantages and limitations, and to date,
there is no gold standard.10,11 As regards the QoL, despite the
fact that HS shows an index greater than any other dermatologic
conditions, there are so far no specific and validated QoL instru-
ments. However, in order to analyse all HS aspects, it is crucial
to define the precise burden of the disease and to objectively
evaluate the rate of HS improvement at baseline and after ther-
apy. In this context, HIDRAdisk, a simple and innovative visual
HS QoL instrument, has been recently psychometrically vali-
dated in Italy demonstrating to improve the management of HS
once implemented in routine clinical practice.4,5 We herein
showed, although in a retrospective study from a single centre,
that improvement in HS after adalimumab treatment measured
with mSS significantly correlated with QoL evaluated by
HIDRAdisk. These results are in line with a recent Italian multi-
center study conducted on 140 HS patients which showed signif-
icant correlation between HIDRAdisk score and HS severity
evaluated through Hurley stage and HS-PGA.5 Moreover, simi-
lar to a previous study,5 we demonstrated that treatment led to
the highest rates of improvement in HIDRAdisk items such as
pain, smell and daily activities. We also highlighted how differ-
ent gender and age may influence disease perception and impact
of HS on QoL. Specifically, we observed that females are linked
to a higher perceived negative impact on QoL and sexual func-
tions as already shown in the literature,12,13 while males rarely
report how the disease may affect intimacy. Interestingly, our
study showed a direct relationship between age and disease dura-
tion: older age and consequent longer HS duration correlated
with a more elevated impact on QoL. It is not surprising that
longer disease duration may lead to increased negative impact
on QoL, discouraging the patient, in line with data previously
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reported by von der Werth et al.14 who observed an indirect cor-
relation between age at HS onset and impact on QoL, showing
that patients with later disease onset experienced a lower impact
on daily life and well-being. Altogether, the data described so far
strongly encourage the dermatologist to be mindful of all clini-
cal, emotional and QoL characteristics of HS patients in order to
achieve an individualized treatment and maximize treatment
outcomes.
In conclusion, approach to HS patients must be personalized
taking into account different factors such as gender,15 age, dis-
ease onset, site of skin lesions, comorbidities, patient’s general
health, sexuality and impact on QoL. Accordingly, HIDRAdisk
appears as a complete and informative tool that can easily mea-
sure the global burden of HS, guiding treatment choices and
evaluating their efficacy.
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